Sanofi (SNY) Net Income towards Common Stockholders (2009 - 2026)

Sanofi has disclosed Net Income towards Common Stockholders across 18 years of filings, most recently posting $398.7 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 91.06% year-over-year to $398.7 million; the TTM figure through Jun 2026 stood at $4.7 billion (down 53.64% YoY), while the FY2025 annual figure was $9.1 billion, up 51.13% from the prior year.
• Net Income towards Common Stockholders came in at $398.7 million for Q2 2026 at Sanofi, down from $1.9 billion in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $10.1 billion in Q3 2025 to a low of -$7.7 billion in Q4 2025.
• Average Net Income towards Common Stockholders over 5 years is $1.9 billion, with a median of $1.9 billion recorded in 2025.
• The largest YoY upside for Net Income towards Common Stockholders was 272.1% in 2025 against a maximum downside of 1543.62% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $5.4 billion in 2022, then tumbled by 111.13% to -$597.1 million in 2023, then surged by 189.3% to $533.2 million in 2024, then tumbled by 1543.62% to -$7.7 billion in 2025, then surged by 105.18% to $398.7 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $398.7 million in Q2 2026, $1.9 billion in Q1 2026, and -$7.7 billion in Q4 2025.